STOCK TITAN

For World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being

Insulet (PODD) launched its “Give Yourself the Freedom to” campaign to encourage people with diabetes to prioritize mental and emotional well-being.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

The “Give Yourself the Freedom to” campaign invites people with diabetes around the world to show themselves compassion and self-care.

Global survey data shows approximately 6 in 10 people with type 1 and type 2 diabetes want more holistic support, including mental health resources.

Insulet is also supporting various diabetes community and colleague engagement initiatives around the globe.

ACTON, Mass.--(BUSINESS WIRE)-- In recognition of World Diabetes Day on November 14, 2026, Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its “Give Yourself the Freedom to” campaign designed to raise awareness of the often overlooked emotional and mental demands of living with diabetes and encourage people living with diabetes to prioritize their own well-being.

“Living with diabetes extends far beyond managing glucose levels and making treatment decisions. It carries a daily mental and emotional burden that can impact every aspect of a person’s life, yet these challenges often go unrecognized,” said Ashley McEvoy, Insulet President and CEO. “Through Insulet’s ‘Give Yourself the Freedom to’ campaign, we are encouraging people with diabetes to prioritize self-care and make space for the moments that bring joy to their lives. Because caring for your mental health is an essential part of caring for your diabetes.”

Insulet commissioned a global survey1 of 9,656 people living with type 1, type 2, and gestational diabetes, as well as caregivers, from 11 different countries. The survey found that 62% of people with type 1 diabetes and 60% of people with type 2 diabetes want more holistic support, including access to mental health resources.

“For years, I measured my diabetes management by my number alone,” said Meg Cremins, Omnipod 5 user2 and diabetes community voice. “Now, I realize that taking care of my mental well-being is just as important as managing my glucose levels. Giving myself five minutes to breathe, reset or step away isn’t being less disciplined about my diabetes care. It's what actually makes me stay engaged and show up for it, every day.”

Throughout November, “Give Yourself the Freedom to” content will be featured across Insulet’s social media channels and shared with Omnipod users, and healthcare providers worldwide.

As part of its commitment to whole person diabetes care, Insulet previously launched a partnership with Calm, a leading consumer mental health company, with the Mind in Range Collection – tailor-made mindfulness tools created specifically for people living with diabetes and their caregivers, including guided meditations, a breathing exercise, and a Sleep Story narrated by Lila Moss3, model and Omnipod user. These resources are designed to fit seamlessly into daily life, without adding another task to the load of managing diabetes. To learn more and explore the free Mind in Range Collection visit the Omnipod × Calm page at omnipod.com/calm.

Additional Diabetes Awareness Month Activities

Throughout Diabetes Awareness month, Insulet is proud to support a range of activities to raise awareness, foster community connections, and give support to people impacted by diabetes.

  • Letters of Encouragement for Children: Through the Insulet for Good program, employees will partner with Breakthrough T1D to write letters of support to newly diagnosed children with type 1 diabetes.
  • Community Event Sponsorships – Insulet is proud to sponsor community events and initiatives led by Type One Together, Risley Health, Stripped Supply, and Fundación Phabian to improve the lives of people affected by diabetes.
  • Employee Events and Activities: In conjunction with Insulet’s Podder® Alliance Network, an employee resource group that includes people living with, caring for, or supporting people with diabetes, the company will host a variety of employee events and engagement opportunities to promote diabetes awareness and community connection.

1Based on an online Censuswide survey, commissioned by Insulet, in Sept. 2025. Results are based upon the responses of 9,656 workers and workers with type 1 or type 2 diabetes across more than 10 sectors in Germany, Netherlands, Saudi Arabia, Spain, Sweden, United Kingdom, United States, Denmark, Australia, Canada, and France.

2Meg Cremins is a paid partner of Omnipod

3Lila Moss is a paid partner of Omnipod

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com and omnipod.com.

©2026 Insulet Corporation. Omnipod and Podder are registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
ir@insulet.com

Media:
Joan Campion
Vice President, External Communications
pr@insulet.com

Source: Insulet Corporation

Key Terms

continuous glucose monitor medical
A continuous glucose monitor is a small device worn on the body that constantly tracks blood sugar levels throughout the day and night. It provides real-time data, helping individuals manage conditions like diabetes more effectively. For investors, advancements in this technology can signal growth opportunities in healthcare and medical device markets, reflecting broader trends in health technology innovation.
subcutaneous drugs medical
Subcutaneous drugs are medicines formulated to be injected just under the skin into fatty tissue, often delivered with a syringe or an auto-injector for at-home use. For investors, this matters because subcutaneous delivery can make treatments more convenient and less costly to administer than hospital-only options, potentially boosting patient uptake, widening the market, and changing manufacturing and reimbursement dynamics—similar to shifting from a hospital drip to a simple home shot.

Keep reading